Autoimmune and non-autoimmune hyperthyroidism in pediatric patients: A review and personal commentary on management

Pediatric Endocrinology Reviews

Volumn 2, Issue 1, 2004, Pages 21-38

  Hung, Wellington ^a   Sarlis, Nicholas J ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

blockers; Graves' disease; Hyperthyroidism; Inorganic iodide; Non autoimmune; Pediatric; Radioactive iodine (or radioiodine); Thyroid storm; Thyroidectomy; Thyrotoxicosis; Thyrotropin; Thyrotropin receptor

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LIOTHYRONINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

AGITATION; AUTOIMMUNE DISEASE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; GRAVES DISEASE; HEART ARRHYTHMIA; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS ADENOMA; PATIENT SELECTION; REVIEW; TACHYCARDIA; THYROID ADENOMA; THYROID CRISIS; THYROID HORMONE RESISTANCE; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN RELEASE; TREMOR;

ADOLESCENT; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERTHYROIDISM; INFANT; INFANT, NEWBORN; IODINE RADIOISOTOPES; MALE; RADIOPHARMACEUTICALS; SURGICAL PROCEDURES, OPERATIVE; THYROID CRISIS; THYROID HORMONES; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 12444293876     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. Bettendorf M. Thyroid disorders in children from birth to adolescence. Eur J Nucl Med 2002;29(Suppl 2):S439-S446
2. Kohn LD, Kosugi S, Ban T, Saji M, Ikuyama S, Giuliani C, Hidaka A, Shimura H, Akamizu T, Tahara K, Amino N. Molecular basis for the autoreactivity against thyroid stimulating hormone receptor. Int Rev Immunol 1992;9:135-165
3. Vaidya B, Kendall-Taylor P, Pearce SHS. The genetics of autoimmune thyroid disease. J Clin Endocrinol Metab 2002;87:5385-5397
4. Watanabe Y, Tahara K, Hirai A, Tada H, Kohn LD, Amino N. Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor. Thyroid 1997;7:13-19
5. Mitsuda N, Tamaki H, Amino N, Hosono T, Miyai K, Tanizawa O. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol 1992;80:359-364
6. Chopra IJ. Fetal and neonatal hyperthyroidism. Thyroid 1992;2:161-163
7. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994;331:1972-1978
8. McKenzie JM, Zakarija M. The clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab 1989;69:1093-1096
9. Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulating immunoglobin and fetal and neonatal thyrotoxicosis. Obstet Gynecol 2002;99:1040-1043
10. Glinoer D. Pregnancy and iodine. Thyroid 2001;11:471-481
11. Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 1983;57:1036-1041
12. Hung W, Sarlis NJ. Molecular genetics of thyroid disorders in the neonate: A review. J Endocrine Genet 2001;2:193-213
13. Kopp P, Jameson JL, Roe TF. Congenital non-autoimmune hyperthyroidism in a non-identical twin caused by a sporadic germline mutation in the thyrotropin receptor gene. Thyroid 1997;7:765-770
14. Esapa CT, Duprez L, Ludgate M, Mustafa MS, Kendall-Taylor P, Vassart G, Harris PE. 1999 A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis. Thyroid 1999;9:1005-1010
15. Alberti L, Proverbio MC, Costagliola S, Weber G, Beck-Peccoz P, Chiumello G, Persani L 2001 A novel germline mutation in the TSH receptor gene causes non-autoimmune autosomal dominant hyperthyroidism. Eur J Endocrinol 2001;145:249-254
16. Lee YS, Poh LKS, Lake KY. An activating mutation of thyrotropin receptor gene in hereditary non-autoimmune hyperthyroidism. J Pediat Endocrinol Metab 2002;15:211-215
17. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G Brief report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995;332:150-154
18. Polak M. Hyperthyroidism in early infancy: Pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid 1998;12:1171-1177
19. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, Weintraub BD. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995;123:572-583
20. Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997;7:433-439
21. LaFranchi SH, Snyder DB, Sesser DE, Skeels MR, Singh N, Brent GA, Nelson JC. Follow-up of newborns with elevated screening T4 concentrations. J Pediatr 2003;143:296-301
22. Fisher DA. Neonatal hyperthyroid screening. J Pediatr 2003;143: 285-287
23. Zimmerman D. Fetal and neonatal hyperthyroidism. Thyroid 1999;9:727-733
24. Cove DR, Johnston P. Fetal hyperthyroidism: Experience of treatment in four siblings. Lancet 1985;1:430-432
25. Polak M, Leger J, Luton D, Any JF, Voillard E, Boissinot C, Czernichow P. Fetal cord blood sampling in the diagnosis and treatment of fetal hyperthyroidism in the offspring of the euthyroid mother producing thyroid-stimulating immunoglobulins. Ann Endocrinol (Paris) 1997;58:338-342
26. Midgley JE. Direct and indirect free thyroxine assay methods: theory and practice. Clin Chem. 2001;47:1353-1363
27. Burrow GN. Thyroid disease, In: Burrow GN, Ferris TF, eds. Medical Complications During Pregnancy, 3rd Ed. Philadelphia: W.B. Saunders, 1998;224-253
28. Diav-Citrin O, Ornoy A. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. Teratology 2002;65:38-44
29. Walter RM, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves disease. Am J Med 1990;88:69-70
30. Karpman BA, Rapaport B, Filetti S, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. J Clin Endocrinol Metab 1987;64:119-123
31. Transue D, Chan J, Kaplan M. Management of neonatal Graves' disease with iopanoic acid. J Pediatr 1992;121:472-474
32. Fontanilla JC, Schneider AB, Sarne DR. The use of oral radiographic contrast agents in the management of hyperthyroidism. Thyroid 2001;11:561-567
33. American Thyroid Association. Statement on ipodate discontinuation. 2000. www.thyroid.org
34. Skuza KA, Sills N, Stene M, Rapoport R. Prediction of neonatal hyperthyroidism in infants born to mothers with Graves' disease. J Pediatr 1995;128:264-267
35. McKenzie JM, Zakarijia M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992;2:155-160
36. Schwab KO, Gerlich M, Broecker M, Sohlemann P, Derwahl M, Lobse MJ. Constitutively active germline mutation of the thyrotropin receptor gene as a cause of congenital hyperthyroidism. J Pediatr 1997;131:899-904
37. Fuhrer D, Paschke R. Thyroid-stimulating hormone receptor mutations: Update and clinical implications. Curr Opin Endocrinol Diabetes 2000;7:288-294
38. Daneman D, Howard NJ Neonatal thyrotoxicosis: Intellectual impairment and craniosynostosis in later years. J Pediatr 1980;97:257-259
39. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;27:109-126
40. LaFranchi S, Hanna CE. Graves' disease in the neonatal period and childhood. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 8th Ed. Philadelphia: Lippincott Williams Wilkins, 2000;989-997.
41. Koch CA, Sarlis NJ. The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. J Endocrinol Invest 2001;24:659-675
42. Gough SCL. The genetics of Graves' disease. Endocrinol Metab Clin North Am 2000;29:255-266
43. Weetman AP. Graves' disease. New Engl J Med 2000;343:1236-1248
44. Wong GWK, Cheng PS. Increasing incidence of childhood Graves' disease in Hong Kong: A follow-up study. Clin Endocrinol (Oxf) 2001;54:547-550
45. Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev 2003;24:668-693
46. Saxena KM, Crawford JD, Talbot NB. Childhood thyrotoxicosis: a long-term perspective. Br Med J 1964;2:1153-1158
47. Vaidya VA, Bongiovanni AM, Parks JS, Tenor A, Kirkland RT. Twenty-two years experience in the medical management of juvenile thyrotoxicosis. Pediatrics 1974;54:565-570
48. Barnes H, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves' disease): Thirty years experience in children and adolescent. J Pediatr 1977;91:313-320
49. Hung W, Wilkins L, Blizzard RM. Medical therapy of thyrotoxicosis in children. Pediatrics 1962;30:17-26
50. Kraiem Z, Newfield RS. Graves' disease in childhood. J Pediatr Endocrinol Metab 2001;14:229-243
51. LaFranchi S, Mandel S. Graves' disease and other forms of hyperthyroidism in infants and children. Curr Opin Endocrinol Diabetes 1996;3:101-109
52. Gruters A. Ocular manifestations in children and adolescents with thyrotoxicosis Exp Clin Endocrinol Diabetes 1999;107(Suppl 5):S172-S174
53. Lueidarme N, Ruiz JC, Czernichow F, Leger J. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease. J Pediatr 2000;137:56-62
54. Radetti G, Bona G, Corrias A, Cappa M, DeSanctis V, Lauriola S, Paganini C, Rigon F. Does Graves' disease during puberty influence adult bone mineral density? Horm Res 2002;58:176-179
55. Stanley JM, Najjar SS. Painful thyroid gland: an atypical presentation of Graves' disease. Clin Endocrinol (Oxf) 1992;37:468-469
56. Alves C, Eidson MS, Zakarija M, McKenzie JM. Graves' disease presenting as painful thyroiditis. Eur J Pediatr 1989;148:603-604
57. Perry LW, Huns W. Atrial fibrillation and hyperthyroidism in a 14-year old boy. J Pediatr 1971;79:668-671
58. Radetti G, Dordi B, Mengarda G, Biscaldi I, Larizza D, Severi F. Thyrotoxicosis presenting with seizures and coma in two children. Am J Dis Child 1993;147:925-926
59. Harland PC, McArthur RG, Fawcett DM. T3 toxicosis in children. Acta Paediatr Scand 1977;66:525-528
60. Foley TP Jr, White C, New A. Juvenile Graves' disease: usefulness and limitations of thyrotropin receptor antibody determinations. J Pediatr 1987;110:378-386
61. Gluck FB, Nusynowitz MI, Plymate S. Chronic lymphocytic thyroiditis, thyrotoxicosis, and low radioactive iodine uptake: Report of four cases. New Engl J Med 1975;293:624-628
62. Doeiter B, Reinehr T, Andler W. Autoimmune thyroiditis in children and adolescents: clinical and laboratory findings in 34 patients. Klin Paediatr 2000;212:103-107 [In German]
63. Masuno M, Kosaka J, Nakamura S. Silent thyroiditis in an eleven-year-old girl, associated with transient increase in serum IgM and thyroid hormone. Endocrinol Jpn 1991;38:219-222
64. Roth C, Scortea M, Stubbe P, Ruschenburg M, Zappel H, Becker W, Lakomek M. Autoimmune thyroiditis in childhood - epidemiology, clinical and laboratory findings in 61 patients. Exp Clin Endocrinol Diabetes 1997;105(Suppl 4):66-69
65. Russell GA, Coulter JB, Isherwood DM, Diver MJ, Smith DS. Autoimmune Addison's disease and thyrotoxic thyroiditis presenting as encephalopathy in twins. Arch Dis Child 1991;66:350-352
66. Suzuki N, Mitamura R, Ohmi H, Itoh Y, Yano K, Okuno A, Tateno M, Itoh T. Hashimoto thyroiditis, distal renal tubular acidosis, pernicious anaemia and encephalopathy: a rare combination of auto-immune disorders in a 12-year-old girl. Eur J Pediatr 1994;153:78-79
67. Graters A. Treatment of Graves' disease in children and adolescents. Horm Res 1998;49:255-257
68. Hung W. Graves' disease in children. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism, 6th ed, St. Louis, MO: Mosby Year Book, Inc., 1997;71-81
69. Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martina E, Kayser L, Delange F. Diagnosis and treatment of thyrotoxicosis in childhood: a European questionaire study. Eur J Endocrinol 1994;131:467-473
70. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Jasefsberg Z, Phillip M. Thyrotoxicosis in prepubertal with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-3682
71. Schulman DI, Muhar I, Jorgensen V, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: Comparison of clinical and biochemical features at diagnosis and response to medical therapy. Thyroid 1997;7:755-760
72. Raza J, Hindmarsh PC, Brook CGD. Thyrotoxicosis in children: Thirty years' experience. Acta Pediatr 1999;88:937-941
73. Bergman P, Auldist AW, Cameron F. Review of the outcome of management of Graves' disease in children and adolescents. J Pediatr Child Health 2001;37:176-182
74. Dotsch J, Siebler T, Hauffa BP, Docker B, Andler W, Bettendorf M, Heinrich U, Goehlke B, Albers N, Willgerodt M, Kiess W. Diagnosis and management of juvenile hyperthyroidism in Germany: A retrospective multicenter study. J Pediatr Endocrinol Metab 2000;13:879-885
75. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children with long-term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241-1245
76. Gartner LA, Path M. Graves' disease in children and adolescents. The Endocrinologist 1995;5:422-430
77. Hoffman WM, Miceli IN. Pharmacokinetics of propylthiouracil in children and adolescents with Graves' disease in the hyperthyroid and euthyroid states. Dev Pharmacol Ther 1988;11:73-81
78. Okuno A, Yano K, Inyaku F, Suzuki Y, Sanae N, Kumai M, Naitoh Y. Pharmacokinetics of methimazole in children and adolescents with Graves' disease. Acta Endocrinol (Copenh) 1987;115:112-118
79. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88:3474-3481
80. Sills IN, Horlick MNB, Rapaport R. Inappropriate suppression of thyrotropin during medical treatment of Graves' disease in childhood. J Pediatr 1992;121:206-209
81. Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an outpatient endocrine clinic. J Clin Endocrinol Metab 1990;71:764-769
82. Brokken LJS, Wiersinga WM, Prummel MF. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients. J Clin Endocrinol Metab 2003;88:4135-4138
83. Gorton C, Sadeghi-Nejad N, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil: Long-term results. Am J Dis Child 1987;141:1084-1086
84. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdif T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001;54:385-390
85. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: The effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med. 1994;87:337-341
86. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T. Administration of thyroxine in treated Graves' disease: Effect on the level of antibodies to thyroid-stimulating hormone receptors and the risk of recurrence of hyperthyroidism. New Engl J Med 1991;324:947-953
87. Tarnai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S. Lack of effect of thyroxine administration on elevated thyroid-stimulating hormone receptor antibody level in treated Graves' disease patients. J Clin Endocrinol Metab 1995;80:1481-1484
88. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lact of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. New Engl J Med 1996;334:220-224
89. Segni M, Leonardi E, Mazzoncini B, Pucarelli I, Pasquino AM. Special features of Graves' disease in early childhood. Thyroid 1999;9:871-877
90. Robinson DC, Hall R, Munro S. Graves' disease, an unusual complication: Raised intracranial pressure due to premature fusion of skull sutures. Arch Dis Child 1969;44:252-257
91. Park RW, Frasier SD. Hyperthyroidism under 2 years of age. Am J Dis Child 1970;120:157-159
92. Kopelman AE. Delayed cerebral development in twins with congenital hyperthyroidism. Am J Dis Child 1983;137:842-845
93. Oppenheimer JH, Schwartz HL. Molecular basis of thyroid hormone-dependent brain development. Endocr Rev 1997;18:462-475
94. Johnsonbaush R, Bryan NR, Hierlwimmer UR, Georges LP. Premature craniosynostosis: A common complication of juvenile hyperthyroidism. J Pediatr 1978;93:188-191
95. Laurberg P, Pedersen RM, Vestergaard H, Sigurdsson G. Goiter size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 1986;111:39-43
96. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82:1719-1726
97. Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: A newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. J Clin Endocrinol Metab 1986;62:980-983
98. Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D. Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab 1999;12:737-541
99. Vitti P, Rago T, Chiovato L, S, Santini F, Fiore E, Rocchi R. Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment Thyroid 1997;7:369-375
100. Winsa B, Dahlberg P, Jansson R, Agren H, Karlson F. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990;122:722-728
101. Cho B, Shong M, Yi K, Lee H, Koh Y, Min H. Evaluation of basal thyrotropin levels and thyrotropin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug therapy in patients with Graves' disease. Clin Endocrinol (Oxf) 1992;36:585-590
102. Bouma OJ, Kammer H, Greer MA. Follow-up comparison of short-term vs. 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease. J Clin Endeocrinol Metab 1982;55:1138-1142
103. Tarnai H, Kasaqi K, Takaichi Y, Takamatsu J, Komaki G, Matsubayashi S, Konishi J, Kuma K, Kumagai LF, Nagataki S. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroid drugs: Clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989;69:49-53
104. Wood LC, Ingbar SH. Hypothyroidism as a late sequel in patients with Graves' disease treated with antithyroid drugs. J Clin Invest 1979;64:1429-1436
105. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with PTU-associated hepatotoxicity: What have we learned? J Clin Endocrinol Metab 1997;82:1727-1733
106. Hung W, August GP. A "collagen-like" syndrome associated antithyroid therapy. J Pediatr 1973;82:852-854
107. Pavia C, Martin MR, Valls C, Palou A. Graves-Basedow disease in a child. Apropos of a case treated with lithium carbonate. An Esp Pediatr 1980;13:1045-1046 [In Spanish]
108. Dotsch J, Rascher W, Dorr HG. Graves disease in childhood: a review of the options for diagnosis and treatment. Paediatr Drugs 2003;5:95-102
109. Hayeck A. Thyroid storm following radioiodine for thyrotoxicosis. J Pediatr 1978;93:978-980
110. Brooks MH, Waldstein CC. Free thyroxine concentrations in thyroid storm. Ann Intern Med 1980;93:694-697
111. Brooks MH, Waldstein SS, Bronsky D, Sterling K. Serum triiodothyronine concentration in thyroid storm. J Clin Endocrinol Metab 1975;40:339-341
112. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: A consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab 2001;86:1865-1867
113. Witte J, Goretzki PE, Roher HD. Surgery for Graves' disease in childhood and adolescence. Exp Clin Endocrinol Diabetes 1997;105:58-60
114. Waldhausen JHT. Controversies related to the medical and surgical management of hyperthyroidism in children. Sem Pediatr Surg 1997;6:121-127
115. Spinelli C, Bertocchini A, Li AM, Miccoli P. Graves-Basedow's disease in children and adolescents: Total vs. subtotal thyroidectomy. Ped Med Chir 2002;23:383-386
116. Rivkees SA, Sklar C, Freemark M. The management of Graves' disease in children with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-3774
117. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-1024
118. Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves' disease: A review with emphasis on radioiodine treatment. Cleve Clin J Med 1988;55:373-382.
119. Clark JD, Gelfand MJ, Elgazzar AH. Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med 1995;36:442-445
120. Povia C, Villanueva J, Valls C, Mane S, Cedo J. Radioiodine therapy for Graves' disease in adolescents: Analysis of 11 patients. The Endocrinologist 2002;12:17-19
121. Cheetham TD, Wraight P, Hughes IA, Barnes ND. Radioiodine treatment of Graves' disease in young people. Horm Res 1998;49:258-262
122. Foley TP Jr, Charron M. Radioiodine treatment of juvenile Graves' disease. Exp Clin Endocrinol Diabetes 1997;101(Suppl 4):61-65
123. Bogozzi F, Martino E, Bartalena L. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no? J Endocrinol Invest 2003;26:174-176
124. Rivkees SA. The use of radioactive iodine in the management of hyperthyroidism in children. Curr Drug Targets Immune Endocr Metab Disord 2001;1:255-264
125. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003;111:745-749
126. Kellerer AM. Risk estimates for radiation-induced cancer - the epidemiological evidence. Radiat Environ Biophys 2000;39:17-24
127. Dooyns BM, Sheline GE, Workman JB, Tomkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: A report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974;38:976-998
128. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002;140:99-103
129. Safa AM, Schumacher P, Rodriquez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131-I) for hyperthyroidism. New Engl J Med 1975;292:167-171
130. Sarfcer SD, Beierwaltes WH, Gill, SP, Cowley BJ. Subsequent fertility and birth histories of children -treated with 131-I for thyroid cancer. J Nucl Med 1976;17:460-464
131. Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131: Optimal therapy for hyperthyroidism in children and adolescents. J Nucl Med 1979;20:847-850
132. Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson U-B, Hallquist A, Lidberg M, Lundell G, Mattson A, Tennvall J, Wiklund K, Holm L-E. Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1-4
133. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-277
134. Inskip PD. Thyroid cancer after radiotherapy for childhood cancer. Med Pediatr Oncol 2001;36:568-573
135. Nakajima H, Sato T, Inoue M, Sana M, Taketani T. 4 Cases of Hashitoxicosis in children. Horumon To Rinsho 1975;23:557-560 [In Japanese]
136. Roldan MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. Diabetes Nutr Metab 1999;12:27-31
137. Rasmussen NC, Hansen JM, Hegedus L. Frequency of thyroiditis and postpartum thyroiditis in a 10-year consecutive hyperthyroid Danish population. Thyroidology 1989;1:143-147
138. Ogawa E, Katsushima Y, Fujiwara I, Iinuma K. Subacute thyroiditis in children: patient report and review of the literature. J Pediatr Endocrinol Metab 2003;16:897-900
139. Foley TP Jr. Thyrotoxicosis in childhood. Pediatr Ann 1992;21:43-39
140. Abe K, Taguchi T, Okuno A, Matsuura N, Sasaki H. Acute suppurative thyroiditis in children. J Pediatr 1979;94:912-914
141. Abe K, Fujita H, Matsuura N, Minami H, Sato T. A fistula from pyriform sinus in recurrent acute suppurative thyroiditis. Am J Dis Child 1981;135:178
142. Chi H, Lee YJ, Chiu NC, Huang FY, Huang CV, Lee KS, Shih SL, Shih BF. Acute suppurative thyroiditis in children. Pediatr Infect Dis J 2002;21:384-387
143. Gevo T, Theodor R. Atypical presentation of subacute thyroiditis. Arch Dis Child 1988;63:845-846
144. Imai C, Kakihara T, Watanabe A, Ikarashi Y, Hotta H, Tanaka A, Uchiyama M. Acute suppurative thyroiditis as a rare complication of aggressive chemotherapy in children with acute myelogeneous leukemia. Pediatr Hematol Oncol 2002;19:247-253
145. Nombo H, Ross JL, Goodman D, Fagin JA. Solitary polyclonal autonomous thyroid nodule: a rare cause of childhood hyperthyroidism. J Clin Endocrinol Metab 1991;72:1108-1112
146. Feuillan PP, Shawker T, Rose SR, Jones J, Jeevanram RK, Nisula BC. Thyroid abnormalities in the McCune-Albright syndrome: ultrasonography and hormonal studies. J Clin Endocrinol Metab 1990;71:1596-1601
147. Perez Parras MA, Marin Paton M, Negrillo Cantero AM, Caro Cruz E, Gonzalez Rivera F, Moreno Carazo A. Amiodarone-induced hyperthyroidism. An Esp Pediatr 2000;53:377-379 [In Spanish]
148. Braverman LE, Roti E. Effects of iodine on thyroid function. Acta Med Austriaca 1996;23:4-9
149. Zois C, Stavrou I, Kalogera C, Svarna E, Dimoliatis I, Seferiadis K, Tsatsoulis A. High prevalence of autoimmune thyroiditis in schoolchildren after elimination of iodine deficiency in northwestern Greece. Thyroid 2003;13:485-489
150. Ven PM. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 2003;14:327-333
151. Matochik JA, Zametkin AJ, Cohen RM, Hauser P, Weintraub BD. Abnormalities in sustained attention and anterior cingulate metabolism in subjects with resistance to thyroid hormone. Brain Res 1996;723:23-28
152. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-486
153. Avramides A, Karapiperis A, Triantafyllidou E, Vayas S, Moshidou A, Vyzantiadis A. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr 1992;81:1058-1060
154. Phillip M, Hershkovitz E, Kornmehl P, Cohen A, Leiberman E. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy. J Pediatr Endocrinol Metab 1995;8:47-50
155. Stanley JM, Najjar SS. Hyperthyroidism secondary to a TSH-secreting pituitary adenoma in a 15-year-old male. Clin Pediatr (Phila) 1991;30:109-111
156. Suntornlohanakul S, Vasiknanont P, Mo-Suwan L, Phuenpathom N, Chongchitnant N. TSH secreting pituitary adenoma in children: a case report. J Med Assoc Thai 1990;73:175-178
157. Litovitz TL, White JD. Levothyroxine ingestions in children: an analysis of 78 cases. Am J Emerg Med 1985;3:297-300
158. Menon PS, Singh GR. Hyperthyroidism in children: an Indian experience. J Pediatr Endocrinol Metab 1996;9:441-446
159. Reiter EO, Root AW, Rettig K, Vargas A. Childhood thyromegaly: recent developments. J Pediatr 1981;99:507-518
160. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002;12:683-702
161. Segni M, Gorman CA. The aftermath of childhood hyperthyroidism. J Pediatr Endocrinol Metab 2001;141277-1282
162. Uretsky SR, Kennerdell JS, Gutai JP. Graves' ophthalmopathy in childhood and adolescence. Arch Opthalmol 1980;98:1963-1964
163. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-4273
164. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-988
165. Fujieda M, Nagata M, Akioka Y, Hattori M, Kawaguchi H, Ito K. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy. Acta Pediatr Jpn 1998;40:286-289
166. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-1738
167. Bartlena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338: 73-78
168. Young LA. Dysthyroid ophthalmopathy in children. J Pediatr Ophthalmol Strabismus 1979;16:105-107
169. Krassas GE. Treatment of juvenile Graves' disease and its ophthalmic complications: the "European way." Eur J Endocrinol 2004;150:407-414
170. Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998;83:3767-3776
171. Liu GT, Heher KL, Katowitz JA, Kazim M, Moazomi G, Moshang T, Teener JW, Sladky J, Volpe NJ, Galetta SL. Prominent proptosis in childhood thyroid eye disease. Ophthalmology 1996;103:779-784
172. Zurakowski D, Di Canzio J, Majzoub JA. Pediatric reference intervals for serum thyroxine, triiodothyronine, thyrotropin, and free thyroxine. Clin Chem 1999;45:1087-1091.